Stock Events

Stock Events

Repare Therapeutics 

$2.59
0
+$0.03+1.17% Monday 07:54

Statistics

Day High
2.59
Day Low
2.54
52W High
-
52W Low
-
Volume
3,008
Avg. Volume
-
Mkt Cap
111.33M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

3MarExpected
Q3 2025
Q4 2025
-0.29
-0.17
-0.04
0.08
Expected EPS
-0.29
Actual EPS
N/A

Financials

-158.37%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
106.95MRevenue
-169.38MNet Income

Analyst Ratings

$3.00Average Price Target
The highest estimate is 3.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RPTX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Repare's precision oncology treatments.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine operates in the genome editing field, directly competing with Repare's DNA damage repair and synthetic lethality approaches.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is a leading developer of CRISPR gene editing treatments, potentially competing with Repare's therapeutic strategies.
Beam Therapeutics
BEAM
Mkt Cap2.51B
Beam Therapeutics focuses on base editing, a form of gene editing that could rival Repare's approach to targeting cancer and other diseases.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics specializes in genomic medicine, including gene editing, competing in the same space as Repare's genomic instability targets.
Allogene Therapeutics
ALLO
Mkt Cap604.57M
Allogene Therapeutics works on allogeneic CAR T cell therapies, which could compete with Repare's approaches in oncology.
Fate Therapeutics
FATE
Mkt Cap141.84M
Fate Therapeutics is developing programmed cellular immunotherapies, competing in the innovative treatment space alongside Repare.
Novartis
NVS
Mkt Cap297.32B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments in oncology, potentially competing across several of Repare's focus areas.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences has a strong presence in oncology and cell therapy, areas where Repare Therapeutics is aiming to make an impact.

About

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.
Show more...
CEO
ISIN
US7602731025

Listings

BOATS
BOATS
RPTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Repare Therapeutics stock price today?▼
The current price of RPTX.BOATS is $2.59 USD — it has increased by +1.17% in the past 24 hours. Watch Repare Therapeutics stock price performance more closely on the chart.
What is Repare Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Repare Therapeutics stocks are traded under the ticker RPTX.BOATS.
What is Repare Therapeutics market cap?▼
Today Repare Therapeutics has the market capitalization of 111.33M
What is Repare Therapeutics revenue for the last year?▼
Repare Therapeutics revenue for the last year amounts to 106.95M USD.
What is Repare Therapeutics net income for the last year?▼
RPTX.BOATS net income for the last year is -169.38M USD.
When did Repare Therapeutics complete a stock split?▼
Repare Therapeutics has not had any recent stock splits.